Erythropoiesis Stimulation in Acute Ischemic Syndromes

Willem Peter T. Ruifrok; Erik Lipšic; Rudolf A. de Boer; Wiek H. van Gilst; Dirk J. van Veldhuisen

doi:10.1016/j.hfc.2009.12.002

Erythropoiesis Stimulation in Acute Ischemic Syndromes

Willem Peter T. Ruifrok^*, Erik Lipšic, Rudolf A. de Boer, Wiek H. van Gilst, Dirk J. van Veldhuisen

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Popular

1 Citation (Scopus)

Abstract

Erythropoietin (EPO) is a hematopoietic hormone with extensive nonhematopoietic properties. The discovery of an EPO receptor outside the hematopoietic system has fuelled research into the beneficial effects of EPO for various conditions, predominantly in cardiovascular disease. Experimental evidence has revealed the cytoprotective properties of EPO, and it seems that the EPO-EPO receptor system provides a powerful backbone against acute myocardial ischemia, gaining from the different properties of EPO. There is an ongoing discussion about possible discrepancy between preclinical and clinical effects of EPO on the cardiovascular system. Large, randomized, placebo-controlled clinical trials are underway to give a final verdict on EPO treatment for acute coronary syndromes.

Original language	English
Pages (from-to)	313-321
Number of pages	9
Journal	Heart Failure Clinics
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.hfc.2009.12.002
Publication status	Published - Jul 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hfc.2009.12.002

Cite this

@article{d0443500351c419ca4e6f6f3af524a4d,

title = "Erythropoiesis Stimulation in Acute Ischemic Syndromes",

abstract = "Erythropoietin (EPO) is a hematopoietic hormone with extensive nonhematopoietic properties. The discovery of an EPO receptor outside the hematopoietic system has fuelled research into the beneficial effects of EPO for various conditions, predominantly in cardiovascular disease. Experimental evidence has revealed the cytoprotective properties of EPO, and it seems that the EPO-EPO receptor system provides a powerful backbone against acute myocardial ischemia, gaining from the different properties of EPO. There is an ongoing discussion about possible discrepancy between preclinical and clinical effects of EPO on the cardiovascular system. Large, randomized, placebo-controlled clinical trials are underway to give a final verdict on EPO treatment for acute coronary syndromes.",

author = "Ruifrok, {Willem Peter T.} and Erik Lip{\v s}ic and {de Boer}, {Rudolf A.} and {van Gilst}, {Wiek H.} and {van Veldhuisen}, {Dirk J.}",

year = "2010",

month = jul,

doi = "10.1016/j.hfc.2009.12.002",

language = "English",

volume = "6",

pages = "313--321",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Erythropoiesis Stimulation in Acute Ischemic Syndromes

AU - Ruifrok, Willem Peter T.

AU - Lipšic, Erik

AU - de Boer, Rudolf A.

AU - van Gilst, Wiek H.

AU - van Veldhuisen, Dirk J.

PY - 2010/7

Y1 - 2010/7

N2 - Erythropoietin (EPO) is a hematopoietic hormone with extensive nonhematopoietic properties. The discovery of an EPO receptor outside the hematopoietic system has fuelled research into the beneficial effects of EPO for various conditions, predominantly in cardiovascular disease. Experimental evidence has revealed the cytoprotective properties of EPO, and it seems that the EPO-EPO receptor system provides a powerful backbone against acute myocardial ischemia, gaining from the different properties of EPO. There is an ongoing discussion about possible discrepancy between preclinical and clinical effects of EPO on the cardiovascular system. Large, randomized, placebo-controlled clinical trials are underway to give a final verdict on EPO treatment for acute coronary syndromes.

AB - Erythropoietin (EPO) is a hematopoietic hormone with extensive nonhematopoietic properties. The discovery of an EPO receptor outside the hematopoietic system has fuelled research into the beneficial effects of EPO for various conditions, predominantly in cardiovascular disease. Experimental evidence has revealed the cytoprotective properties of EPO, and it seems that the EPO-EPO receptor system provides a powerful backbone against acute myocardial ischemia, gaining from the different properties of EPO. There is an ongoing discussion about possible discrepancy between preclinical and clinical effects of EPO on the cardiovascular system. Large, randomized, placebo-controlled clinical trials are underway to give a final verdict on EPO treatment for acute coronary syndromes.

UR - http://www.scopus.com/inward/record.url?scp=77953557288&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2009.12.002

DO - 10.1016/j.hfc.2009.12.002

M3 - Review article

C2 - 20630406

AN - SCOPUS:77953557288

SN - 1551-7136

VL - 6

SP - 313

EP - 321

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 3

ER -

Erythropoiesis Stimulation in Acute Ischemic Syndromes

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this